FIELD: pharmaceuticals.
SUBSTANCE: invention relates to novel solid-phase methods for peptide synthesis of analogues which exhibit oxytocin antagonist activity, especially barusiban and intermediate compounds thereof. In particular, the present invention relates to a solid-phase method of producing a compound having formula c[AA1-AA6]-AA7-ol, where AA1 is propionic acid, AA2 preferably represents D-Trp, AA3 represents Ile, AA4 preferably represents AlloIle, AA5 represents Asn, AA6 is Hcy, and AA7 preferably is N-Me-Orn-ol, or its pharmaceutically acceptable salt or solvate.
EFFECT: method demonstrates better reliability and is well adapted to obtain proper purity and output, which makes it suitable for large-scale production.
15 cl, 11 dwg, 5 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PRODUCTION OF DEGARELIX AND INTERMEDIATE COMPOUNDS THEREOF | 2011 |
|
RU2602042C2 |
EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
PEPTIDE COMPOUNDS | 2007 |
|
RU2415149C2 |
PEPTIDE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1994 |
|
RU2100369C1 |
OXYTOCIN RECEPTOR AGONISTS | 2010 |
|
RU2539692C2 |
OXYTOCIN ANALOGUES | 2009 |
|
RU2496788C2 |
GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
NEW OCTAPEPTIDE COMPOUNDS AND THEIR THERAPEUTIC APPLICATION | 2011 |
|
RU2595525C2 |
PEPTIDE ANALOGUES GH-RH WITH OPPOSING ACTION, WAY OF DEPRESSION OF GH LEVEL, WAY OF DEPRESSION OF IGF-INIGF-II LEVEL, APPLICATION FOR INHIBITION OF GROWTH OF CANCER CELLS, PHARMACOLOGICALLY ACCEPTABLE COMPOSITION (VARIANTS) | 2004 |
|
RU2335506C2 |
Authors
Dates
2020-07-14—Published
2016-10-06—Filed